International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 5, Issue 9 | Research Article | Open Access
Tessy Lopez-Goerne*
Tessy Lopez-Goerne1,2*, Francisco Padilla Godinez1, Antonela Gonzalez-Bondani1, Rafael Valiente1, Vicente González-Carranza3, Daniel Álvarez-Amador1, Abel Santamaria1
1Department of Health Care, Autonomous Metropolitan University – Xochimilco, Mexico City 04960, Mexico
2Laboratory of Nanotechnology, Department Tulane University New Orleans USA
*Correspondence to: Tessy Lopez-Goerne
Fulltext PDFGangliogliomas are rare, low-grade neuroglial tumours predominantly affecting children and adolescents, frequently presenting with drug-resistant epilepsy. Despite surgical resection and adjuvant therapies, recurrence is common, especially when total resection is not feasible. This case study reports on a 12-year-old female with a recurrent ganglioglioma treated with conventional therapies—surgery, chemotherapy, and radiotherapy—followed by a novel nanomedicine intervention using platinum-based bionanocatalysts. These bionanocatalysts (Pt/TiO₂), synthesized via sol-gel methods, were engineered for high selectivity and catalytic activity within malignant cells. Comprehensive characterization through TEM, SEM, EDS, FTIR, Raman spectroscopy, and XRD confirmed their nanoscale structure, anatase crystalline phase, and high surface area (515 m²/g). The patient received intratumoral implantation of these nanoparticles during her final surgical procedure. Subsequent follow-up over two years revealed no recurrence of tumour or neurological sequelae. The catalytic mechanism involves radical generation (O₂•⁻, HO₂•, OH•), facilitating oxidative degradation of cancerous tissue. Histopathology confirmed the biphasic nature of the ganglioglioma, and imaging studies tracked tumour progression and response to treatment. This report underscores the potential of heterogeneous catalytic nanomedicine as a complementary approach to conventional treatments for refractory brain tumours. The case demonstrates that bionanocatalysts offer targeted tumour destruction with minimal systemic toxicity, presenting a promising avenue for future neuro-oncological therapies.
Bionanocatalyst; Ganglioglioma; Platinum; Catalytic Nanomedicine; Neuro-oncology
Tessy Lopez-Goerne, Francisco Padilla Godinez, Antonela Gonzalez-Bondani, Rafael Valiente, Vicente González-Carranza, Daniel Álvarez-Amador, et al. Catalytic Nanomedicine: Ganglioglioma Treated with Bionanocatalysts in Mexico. Int Clinc Med Case Rep Jour. 2026;5(9):1-13.